TAT(SZ:002433)2022-06-15 16:00Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2021, representing a year-on-year increase of 15%[18]. - The net profit attributable to shareholders was 150 million RMB, an increase of 10% compared to the previous year[18]. - The company's operating revenue for 2021 was ¥2,264,174,816.08, a decrease of 36.79% compared to ¥3,581,948,583.92 in 2020[23]. - The net profit attributable to shareholders was a loss of ¥803,289,348.21, a decline of 3,714.24% from a profit of ¥22,225,674.49 in 2020[23]. - The total assets at the end of 2021 were ¥7,628,958,587.57, down 15.95% from ¥9,077,058,813.52 at the end of 2020[23]. - The company's basic and diluted earnings per share were both -¥1.05, a decrease of 3,600.00% from ¥0.03 in 2020[23]. - The company reported a significant net loss primarily due to goodwill impairment and losses from asset divestiture[28]. - The company achieved total operating revenue of ¥2,264,174,816.08, a decrease of 36.79% compared to the same period last year[35]. - The operating profit was -¥835,222,061.16, a decline of 2075.50% year-on-year[35]. - The net profit attributable to shareholders was -¥831,921,272.02, a drop of 3193.93% compared to the previous year[35]. Research and Development - The company plans to invest 200 million RMB in research and development for new products and technologies in 2022[18]. - The company invested in R&D, completing projects such as the secondary development of the traditional Chinese medicine Qilin Wan and the IV phase clinical research of a new drug[36]. - The company plans to continue investing in the research and market development of its leading product, Qilin Wan, to capitalize on the growing demand in the reproductive health market[53]. - Research and development (R&D) investment increased by 49.16% year-on-year to CNY 30,400,042.44, representing 1.34% of operating revenue, up from 0.57%[74]. - The company is committed to increasing research and development efforts, including the development of new drug formulations and collaborations with academic institutions[103]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 30% increase in market share within the next three years[18]. - Future guidance estimates a revenue growth of 20% for 2022, driven by new product launches and market expansion efforts[18]. - The company is actively expanding its "Internet + Medicine" business model to enhance user convenience and integrate various healthcare services[44]. - The company aims to improve its industry position through resource integration, product innovation, and market expansion[34]. - The company is exploring new market opportunities and product development to enhance its competitive position in the pharmaceutical sector[96]. Operational Efficiency - The company emphasizes a commitment to maintaining high standards in manufacturing practices, adhering to GMP and GSP regulations[18]. - The company has constructed intelligent production facilities to enhance automation and efficiency in its manufacturing processes[51]. - The company has established a management academy for ongoing employee training, focusing on various operational and safety standards[143]. - The company has implemented measures to reduce carbon emissions and improve energy efficiency through process improvements[154]. - The company has improved its governance structure and internal control systems to protect shareholder rights[155]. Customer and User Engagement - User data indicates a growth of 25% in the customer base, reaching 1.5 million active users by the end of 2021[18]. - As of the end of the reporting period, the total registered members reached 84.4 million, with 73.33 million purchasing users[39]. - The company has over 73 million transaction members in its e-commerce platform, 康爱多, enhancing its market reach and customer engagement[54]. - 康爱多 has established stable strategic partnerships with over 3,000 industrial enterprises, ensuring a robust supply chain with over 28,000 online SKUs[55]. Financial Management and Governance - The company has established a robust governance structure, complying with relevant laws and regulations, and ensuring fair treatment of all shareholders, especially minority shareholders[111]. - The company has a dedicated internal audit department that supervises the establishment and implementation of internal control systems, ensuring the authenticity and completeness of financial information[112]. - The company has a structured remuneration process for its directors and senior management, ensuring competitive compensation aligned with industry standards[129]. - The company has maintained a high level of attendance at board meetings, with no directors missing two consecutive meetings[134]. - The company has not faced any penalties from securities regulatory agencies in the past three years, indicating compliance and good governance practices[129]. Social Responsibility and Environmental Commitment - The company emphasizes its commitment to social responsibility and has consistently increased tax contributions to local and national governments over the years[157]. - The company adheres to environmental protection laws and regulations, ensuring compliance with pollution control measures[156]. - The company has not reported any significant environmental violations in the past three years[156]. - Environmental protection is a priority for the company, which adheres to higher standards than national regulations and anticipates increased operational costs due to stricter future environmental requirements[105]. Challenges and Risks - The company faces risks from fluctuating national pharmaceutical policies, raw material costs, market competition, and stringent regulatory requirements[104]. - The overall performance of the company was impacted by the transfer of remaining equity stakes in subsidiaries, leading to a net loss of 8.16 million yuan[96]. - The company is actively working to mitigate the potential risks highlighted in the audit report to ensure sustainable and healthy growth[165].